Fri Jun 14 09:06:57 2024
EVENTS
 FREE
SOFTWARE
INSTITUTE

POLITICS
JOBS
MEMBERS'
CORNER

MAILING
LIST

NYLXS Mailing Lists and Archives
NYLXS Members have a lot to say and share but we don't keep many secrets. Join the Hangout Mailing List and say your peice.

DATE 2018-01-01

HANGOUT

2024-06-14 | 2024-05-14 | 2024-04-14 | 2024-03-14 | 2024-02-14 | 2024-01-14 | 2023-12-14 | 2023-11-14 | 2023-10-14 | 2023-09-14 | 2023-08-14 | 2023-07-14 | 2023-06-14 | 2023-05-14 | 2023-04-14 | 2023-03-14 | 2023-02-14 | 2023-01-14 | 2022-12-14 | 2022-11-14 | 2022-10-14 | 2022-09-14 | 2022-08-14 | 2022-07-14 | 2022-06-14 | 2022-05-14 | 2022-04-14 | 2022-03-14 | 2022-02-14 | 2022-01-14 | 2021-12-14 | 2021-11-14 | 2021-10-14 | 2021-09-14 | 2021-08-14 | 2021-07-14 | 2021-06-14 | 2021-05-14 | 2021-04-14 | 2021-03-14 | 2021-02-14 | 2021-01-14 | 2020-12-14 | 2020-11-14 | 2020-10-14 | 2020-09-14 | 2020-08-14 | 2020-07-14 | 2020-06-14 | 2020-05-14 | 2020-04-14 | 2020-03-14 | 2020-02-14 | 2020-01-14 | 2019-12-14 | 2019-11-14 | 2019-10-14 | 2019-09-14 | 2019-08-14 | 2019-07-14 | 2019-06-14 | 2019-05-14 | 2019-04-14 | 2019-03-14 | 2019-02-14 | 2019-01-14 | 2018-12-14 | 2018-11-14 | 2018-10-14 | 2018-09-14 | 2018-08-14 | 2018-07-14 | 2018-06-14 | 2018-05-14 | 2018-04-14 | 2018-03-14 | 2018-02-14 | 2018-01-14 | 2017-12-14 | 2017-11-14 | 2017-10-14 | 2017-09-14 | 2017-08-14 | 2017-07-14 | 2017-06-14 | 2017-05-14 | 2017-04-14 | 2017-03-14 | 2017-02-14 | 2017-01-14 | 2016-12-14 | 2016-11-14 | 2016-10-14 | 2016-09-14 | 2016-08-14 | 2016-07-14 | 2016-06-14 | 2016-05-14 | 2016-04-14 | 2016-03-14 | 2016-02-14 | 2016-01-14 | 2015-12-14 | 2015-11-14 | 2015-10-14 | 2015-09-14 | 2015-08-14 | 2015-07-14 | 2015-06-14 | 2015-05-14 | 2015-04-14 | 2015-03-14 | 2015-02-14 | 2015-01-14 | 2014-12-14 | 2014-11-14 | 2014-10-14 | 2014-09-14 | 2014-08-14 | 2014-07-14 | 2014-06-14 | 2014-05-14 | 2014-04-14 | 2014-03-14 | 2014-02-14 | 2014-01-14 | 2013-12-14 | 2013-11-14 | 2013-10-14 | 2013-09-14 | 2013-08-14 | 2013-07-14 | 2013-06-14 | 2013-05-14 | 2013-04-14 | 2013-03-14 | 2013-02-14 | 2013-01-14 | 2012-12-14 | 2012-11-14 | 2012-10-14 | 2012-09-14 | 2012-08-14 | 2012-07-14 | 2012-06-14 | 2012-05-14 | 2012-04-14 | 2012-03-14 | 2012-02-14 | 2012-01-14 | 2011-12-14 | 2011-11-14 | 2011-10-14 | 2011-09-14 | 2011-08-14 | 2011-07-14 | 2011-06-14 | 2011-05-14 | 2011-04-14 | 2011-03-14 | 2011-02-14 | 2011-01-14 | 2010-12-14 | 2010-11-14 | 2010-10-14 | 2010-09-14 | 2010-08-14 | 2010-07-14 | 2010-06-14 | 2010-05-14 | 2010-04-14 | 2010-03-14 | 2010-02-14 | 2010-01-14 | 2009-12-14 | 2009-11-14 | 2009-10-14 | 2009-09-14 | 2009-08-14 | 2009-07-14 | 2009-06-14 | 2009-05-14 | 2009-04-14 | 2009-03-14 | 2009-02-14 | 2009-01-14 | 2008-12-14 | 2008-11-14 | 2008-10-14 | 2008-09-14 | 2008-08-14 | 2008-07-14 | 2008-06-14 | 2008-05-14 | 2008-04-14 | 2008-03-14 | 2008-02-14 | 2008-01-14 | 2007-12-14 | 2007-11-14 | 2007-10-14 | 2007-09-14 | 2007-08-14 | 2007-07-14 | 2007-06-14 | 2007-05-14 | 2007-04-14 | 2007-03-14 | 2007-02-14 | 2007-01-14 | 2006-12-14 | 2006-11-14 | 2006-10-14 | 2006-09-14 | 2006-08-14 | 2006-07-14 | 2006-06-14 | 2006-05-14 | 2006-04-14 | 2006-03-14 | 2006-02-14 | 2006-01-14 | 2005-12-14 | 2005-11-14 | 2005-10-14 | 2005-09-14 | 2005-08-14 | 2005-07-14 | 2005-06-14 | 2005-05-14 | 2005-04-14 | 2005-03-14 | 2005-02-14 | 2005-01-14 | 2004-12-14 | 2004-11-14 | 2004-10-14 | 2004-09-14 | 2004-08-14 | 2004-07-14 | 2004-06-14 | 2004-05-14 | 2004-04-14 | 2004-03-14 | 2004-02-14 | 2004-01-14 | 2003-12-14 | 2003-11-14 | 2003-10-14 | 2003-09-14 | 2003-08-14 | 2003-07-14 | 2003-06-14 | 2003-05-14 | 2003-04-14 | 2003-03-14 | 2003-02-14 | 2003-01-14 | 2002-12-14 | 2002-11-14 | 2002-10-14 | 2002-09-14 | 2002-08-14 | 2002-07-14 | 2002-06-14 | 2002-05-14 | 2002-04-14 | 2002-03-14 | 2002-02-14 | 2002-01-14 | 2001-12-14 | 2001-11-14 | 2001-10-14 | 2001-09-14 | 2001-08-14 | 2001-07-14 | 2001-06-14 | 2001-05-14 | 2001-04-14 | 2001-03-14 | 2001-02-14 | 2001-01-14 | 2000-12-14 | 2000-11-14 | 2000-10-14 | 2000-09-14 | 2000-08-14 | 2000-07-14 | 2000-06-14 | 2000-05-14 | 2000-04-14 | 2000-03-14 | 2000-02-14 | 2000-01-14 | 1999-12-14

Key: Value:

Key: Value:

MESSAGE
DATE 2018-01-08
FROM Ruben Safir
SUBJECT Subject: [Hangout - NYLXS] The scam that is your healthcare insurance - how
From hangout-bounces-at-nylxs.com Mon Jan 8 18:46:51 2018
Return-Path:
X-Original-To: archive-at-mrbrklyn.com
Delivered-To: archive-at-mrbrklyn.com
Received: from www2.mrbrklyn.com (www2.mrbrklyn.com [96.57.23.82])
by mrbrklyn.com (Postfix) with ESMTP id 1B9BC161132;
Mon, 8 Jan 2018 18:46:50 -0500 (EST)
X-Original-To: hangout-at-nylxs.com
Delivered-To: hangout-at-nylxs.com
Received: from mailbackend.panix.com (mailbackend.panix.com [166.84.1.89])
by mrbrklyn.com (Postfix) with ESMTP id 7F55C161132
for ; Mon, 8 Jan 2018 18:46:44 -0500 (EST)
Received: from panix2.panix.com (panix2.panix.com [166.84.1.2])
by mailbackend.panix.com (Postfix) with ESMTP id 0CF7E2A82B
for ; Mon, 8 Jan 2018 18:46:43 -0500 (EST)
Received: by panix2.panix.com (Postfix, from userid 20529)
id E9F6A33C79; Mon, 8 Jan 2018 18:46:43 -0500 (EST)
Date: Mon, 8 Jan 2018 18:46:43 -0500
From: Ruben Safir
To: NYLXS
Message-ID: <20180108234643.GA2513-at-panix.com>
MIME-Version: 1.0
User-Agent: Mutt/1.8.2 (2017-04-18)
Subject: [Hangout - NYLXS] The scam that is your healthcare insurance - how
the insurance companiess rip you off
X-BeenThere: hangout-at-nylxs.com
X-Mailman-Version: 2.1.17
Precedence: list
List-Id: NYLXS Tech Talk and Politics
List-Unsubscribe: ,

List-Post:
List-Help:
List-Subscribe: ,

Content-Type: multipart/mixed; boundary="===============0774426847=="
Errors-To: hangout-bounces-at-nylxs.com
Sender: "Hangout"

--===============0774426847==
Content-Type: text/plain; charset=unknown-8bit
Content-Disposition: inline
Content-Transfer-Encoding: quoted-printable

The One that Broke the Camel's Back: DIR Fees Set to Catalyze Transparency =
Discussion With a Wider Audience
MARCH 20, 2017
Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor-in-Chief
DIR Fees: the Latest in a Long Line of Spread Strategies
Pharmacy benefit managers (PBMs) play an important and necessary role withi=
n our private system of health care. Because there is no central authority =
to set prices for drugs, PBMs step in to create a marketplace (of sorts) fo=
r buyers and sellers. They also provide administrative functions, such as a=
djudicating claims and writing checks on behalf of the payer. The 3 largest=
PBMs handle billions of transactions a year, ostensibly to generate operat=
ing revenue. However, these transactions are largely a commodity. So to sup=
plement that revenue in order to generate profits, spread strategies need t=
o be employed. Spread occurs when a portion of the buy=E2=80=93sell differe=
nce can be retained by a PBM. This is akin to the house=E2=80=99s take in a=
casino (except with nobody knowing what the percentage =E2=80=9Ctake=E2=80=
=9D is). Direct and indirect remuneration (DIR) fees are the latest in a lo=
ng line of reimbursement strategies that rely on spread that generate margi=
n for PBMs.
=20
Transparency Is the Kryptonite of Any Spread Business
Squeezing one end of the proverbial margin balloon results in the other end=
getting bigger. In the case of DIR fees, the federal government wanted a c=
learer view into the spread and to receive a bigger part of that spread. Th=
us, the payer side of the balloon got squeezed. As a result, community phar=
macies, by and large, ended up rebalancing the air in the balloon on the ot=
her side through DIR fees, which are simply a way to package the PBM margin=
in another way and place the burden of that spread on the pharmacy. The pa=
ckage may include network access fees, performance tiering, and other attri=
butions of apportionment. It can be anything that is assigned to the dollar=
amount in total. This strategy is only possible (politically or otherwise)=
through lack of transparency in the clawback provisions. Although good at =
generating profit, lack of transparency is an anathema to properly function=
ing marketplaces. Remember collateralized debt obligations and the financia=
l crisis? Nobody had any idea what was in those packaged debt vehicles; not=
the buyers or sellers, just the people who created them.
=20
No Longer Inside Baseball: The Transparency Discussion Goes Mainstream
Part of the challenge of pushing back against lack of transparency in pharm=
acy reimbursement is that it comes across as esoteric, with highly technica=
l rebate structures and multiple parties involved under the surface, but wi=
thout a lot of fanfare the average person can understand or attach much emo=
tion to because transparency is a matter between providers and payers. Howe=
ver, several catalyzers now in play are changing that dynamic and widening =
the aperture of the discussion to include mainstream policymakers and media=
channels:
=20
Catalyzer #1: DIR Fees Were Born out of Regulation to Create Transparency f=
or the Government
Anytime a program that involves government is implemented, it will ultimate=
ly be subject to public scrutiny, open forums, and disclosure. Avenues to e=
ngage, if you are a patient advocate or a provider advocate, are much more =
plentiful. DIR fees (and ultimately, spread itself) will likely be the issu=
e that pierces the transparency veil of all mechanisms that create spread b=
ecause the rules and procedures around government make the discussion hard =
to hide.
=20
Catalyzer #2: DIR Fees Require Opacity to Generate Margin
Spread margin is an animal of opacity. In the absence of nondisclosure and =
in a transparent environment, margin is generated as a fee (not spread). DI=
R fees require opacity to exist. The country=E2=80=99s mood is currently no=
t favorable toward the guy behind the curtain.
=20
Catalyzer #3: DIR Fees Affect the Consumer
Recent reporting has uncovered ways in which DIR fees may affect consumers =
and their out-of-pocket spend. That is a game changer when it comes to broa=
dening the audience of the interested.
=20
Catalyzer #4: President Trump=E2=80=99s Populist Stance on Drug Costs
This one is the kicker. For years, pharmacies and Pharmaceutical Research a=
nd Manufacturers of America (PhRMA) have been at odds during budget season =
because both contribute to the total cost of drugs, fighting over therapeut=
ic interchange and pharmacy reimbursement cuts as the way to moderate incre=
asing costs. However, as PhRMA and pharmacies have been squeezed over time,=
the portion of available margin going to these 2 stakeholders has come mor=
e in line per transaction with PBM spread. This has had the effect of bring=
ing otherwise warring parties closer together to spotlight the PBM industry=
=E2=80=99s role as part of the drug cost driver equation (which is the oppo=
site of its intended market purpose). The fact that a Republican is proposi=
ng price controls will shine a $300 billion-watt bulb on how drugs are purc=
hased and reimbursed through the entire value chain.
=20
Catalyzer #5: Legislation (Regardless of Outcomes)
No proposed or introduced legislation is worth a darn unless it has broad p=
olitical momentum behind it. Legislators can introduce legislation all day =
long that gets referred to committee, with no hearings or fanfare. However,=
because of catalyzers 1 through 4 above, House Resolution 1038 and Senate =
Bill 413, which speak to transparency, now have legs. And even if they neve=
r reach a vote, they will no doubt have a much wider audience, and that is =
a game changer.
=20

--===============0774426847==
Content-Type: text/plain; charset="us-ascii"
MIME-Version: 1.0
Content-Transfer-Encoding: 7bit
Content-Disposition: inline

_______________________________________________
Hangout mailing list
Hangout-at-nylxs.com
http://lists.mrbrklyn.com/mailman/listinfo/hangout

--===============0774426847==--

--===============0774426847==
Content-Type: text/plain; charset=unknown-8bit
Content-Disposition: inline
Content-Transfer-Encoding: quoted-printable

The One that Broke the Camel's Back: DIR Fees Set to Catalyze Transparency =
Discussion With a Wider Audience
MARCH 20, 2017
Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor-in-Chief
DIR Fees: the Latest in a Long Line of Spread Strategies
Pharmacy benefit managers (PBMs) play an important and necessary role withi=
n our private system of health care. Because there is no central authority =
to set prices for drugs, PBMs step in to create a marketplace (of sorts) fo=
r buyers and sellers. They also provide administrative functions, such as a=
djudicating claims and writing checks on behalf of the payer. The 3 largest=
PBMs handle billions of transactions a year, ostensibly to generate operat=
ing revenue. However, these transactions are largely a commodity. So to sup=
plement that revenue in order to generate profits, spread strategies need t=
o be employed. Spread occurs when a portion of the buy=E2=80=93sell differe=
nce can be retained by a PBM. This is akin to the house=E2=80=99s take in a=
casino (except with nobody knowing what the percentage =E2=80=9Ctake=E2=80=
=9D is). Direct and indirect remuneration (DIR) fees are the latest in a lo=
ng line of reimbursement strategies that rely on spread that generate margi=
n for PBMs.
=20
Transparency Is the Kryptonite of Any Spread Business
Squeezing one end of the proverbial margin balloon results in the other end=
getting bigger. In the case of DIR fees, the federal government wanted a c=
learer view into the spread and to receive a bigger part of that spread. Th=
us, the payer side of the balloon got squeezed. As a result, community phar=
macies, by and large, ended up rebalancing the air in the balloon on the ot=
her side through DIR fees, which are simply a way to package the PBM margin=
in another way and place the burden of that spread on the pharmacy. The pa=
ckage may include network access fees, performance tiering, and other attri=
butions of apportionment. It can be anything that is assigned to the dollar=
amount in total. This strategy is only possible (politically or otherwise)=
through lack of transparency in the clawback provisions. Although good at =
generating profit, lack of transparency is an anathema to properly function=
ing marketplaces. Remember collateralized debt obligations and the financia=
l crisis? Nobody had any idea what was in those packaged debt vehicles; not=
the buyers or sellers, just the people who created them.
=20
No Longer Inside Baseball: The Transparency Discussion Goes Mainstream
Part of the challenge of pushing back against lack of transparency in pharm=
acy reimbursement is that it comes across as esoteric, with highly technica=
l rebate structures and multiple parties involved under the surface, but wi=
thout a lot of fanfare the average person can understand or attach much emo=
tion to because transparency is a matter between providers and payers. Howe=
ver, several catalyzers now in play are changing that dynamic and widening =
the aperture of the discussion to include mainstream policymakers and media=
channels:
=20
Catalyzer #1: DIR Fees Were Born out of Regulation to Create Transparency f=
or the Government
Anytime a program that involves government is implemented, it will ultimate=
ly be subject to public scrutiny, open forums, and disclosure. Avenues to e=
ngage, if you are a patient advocate or a provider advocate, are much more =
plentiful. DIR fees (and ultimately, spread itself) will likely be the issu=
e that pierces the transparency veil of all mechanisms that create spread b=
ecause the rules and procedures around government make the discussion hard =
to hide.
=20
Catalyzer #2: DIR Fees Require Opacity to Generate Margin
Spread margin is an animal of opacity. In the absence of nondisclosure and =
in a transparent environment, margin is generated as a fee (not spread). DI=
R fees require opacity to exist. The country=E2=80=99s mood is currently no=
t favorable toward the guy behind the curtain.
=20
Catalyzer #3: DIR Fees Affect the Consumer
Recent reporting has uncovered ways in which DIR fees may affect consumers =
and their out-of-pocket spend. That is a game changer when it comes to broa=
dening the audience of the interested.
=20
Catalyzer #4: President Trump=E2=80=99s Populist Stance on Drug Costs
This one is the kicker. For years, pharmacies and Pharmaceutical Research a=
nd Manufacturers of America (PhRMA) have been at odds during budget season =
because both contribute to the total cost of drugs, fighting over therapeut=
ic interchange and pharmacy reimbursement cuts as the way to moderate incre=
asing costs. However, as PhRMA and pharmacies have been squeezed over time,=
the portion of available margin going to these 2 stakeholders has come mor=
e in line per transaction with PBM spread. This has had the effect of bring=
ing otherwise warring parties closer together to spotlight the PBM industry=
=E2=80=99s role as part of the drug cost driver equation (which is the oppo=
site of its intended market purpose). The fact that a Republican is proposi=
ng price controls will shine a $300 billion-watt bulb on how drugs are purc=
hased and reimbursed through the entire value chain.
=20
Catalyzer #5: Legislation (Regardless of Outcomes)
No proposed or introduced legislation is worth a darn unless it has broad p=
olitical momentum behind it. Legislators can introduce legislation all day =
long that gets referred to committee, with no hearings or fanfare. However,=
because of catalyzers 1 through 4 above, House Resolution 1038 and Senate =
Bill 413, which speak to transparency, now have legs. And even if they neve=
r reach a vote, they will no doubt have a much wider audience, and that is =
a game changer.
=20

--===============0774426847==
Content-Type: text/plain; charset="us-ascii"
MIME-Version: 1.0
Content-Transfer-Encoding: 7bit
Content-Disposition: inline

_______________________________________________
Hangout mailing list
Hangout-at-nylxs.com
http://lists.mrbrklyn.com/mailman/listinfo/hangout

--===============0774426847==--

  1. 2018-01-05 Ruben Safir <mrbrklyn-at-panix.com> Subject: [Hangout - NYLXS] archive work
  2. 2018-01-05 Ruben Safir <mrbrklyn-at-panix.com> Subject: [Hangout - NYLXS] one last archive :(
  3. 2018-01-07 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] Check this out...
  4. 2018-01-08 Gabor Szabo <gabor-at-szabgab.com> Subject: [Hangout - NYLXS] [Perlweekly] #337 - CPAN Pull Request Challenge
  5. 2018-01-08 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] Tzfat Prehistoric Archeaology
  6. 2018-01-08 Ruben Safir <mrbrklyn-at-panix.com> Subject: [Hangout - NYLXS] The scam that is your healthcare insurance - how
  7. 2018-01-10 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] Fwd: The Intel Management Engine: an attack on
  8. 2018-01-09 From: "IEEE The Institute Alert" <reply-at-media.ieee.org> Subject: [Hangout - NYLXS] Job Ads on Facebook Discriminate Against Older
  9. 2018-01-11 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] Fwd: Fwd: Re: [opensuse] Q re earlier versions of
  10. 2018-01-12 Ruben Safir <mrbrklyn-at-panix.com> Subject: [Hangout - NYLXS] american flagg
  11. 2018-01-11 IEEE Engineering in Medicine and Biology Society <noreply-at-embs.org> Subject: [Hangout - NYLXS] See What's New This Week in EMBS!!!!
  12. 2018-01-14 Gabor Szabo <szabgab-at-gmail.com> Subject: [Hangout - NYLXS] [Israel.pm] Contributing to Open Source projects
  13. 2018-01-15 From: =?UTF-8?Q?dawidmazurek=40wp=2Epl?= <dawidmazurek-at-wp.pl> Subject: [Hangout - NYLXS] [dinosaur] Caihong juji gen. et sp. nov.
  14. 2018-01-15 Ben Creisler <bcreisler-at-gmail.com> Re: [Hangout - NYLXS] [dinosaur] Dinosaurs,
  15. 2018-01-15 Gabor Szabo <gabor-at-szabgab.com> Subject: [Hangout - NYLXS] [Perlweekly] #338 - Halfway through January
  16. 2018-01-15 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] Lets take a poll
  17. 2018-01-15 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] Movies of the week
  18. 2018-01-15 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout - NYLXS] Movies of the week
  19. 2018-01-15 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout - NYLXS] Lets take a poll
  20. 2018-01-16 Ruben Safir <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] Reminiscing
  21. 2018-01-16 Ruben Safir <mrbrklyn-at-panix.com> Re: [Hangout - NYLXS] Reminiscing
  22. 2018-01-16 Ruben Safir <ruben-at-mrbrklyn.com> Re: [Hangout - NYLXS] Reminiscing
  23. 2018-01-16 From: "Free Software Foundation" <info-at-fsf.org> Subject: [Hangout - NYLXS] The 2018 LibrePlanet keynotes are here -- you
  24. 2018-01-17 From: "IEEE Communications Society" <noreply-at-comsoc.org> Subject: [Hangout - NYLXS] The IEEE Summit on Communications Futures is 2
  25. 2018-01-16 RestorationART <restorationart-at-restorationplaza.org> Subject: [Hangout - NYLXS] The Golden Age of Black Theater Conversation,
  26. 2018-01-15 Ruben Safir <ruben.safir-at-my.liu.edu> Re: [Hangout - NYLXS] Lets take a poll
  27. 2018-01-19 From: "Dana Morgenstein" <info-at-fsf.org> Subject: [Hangout - NYLXS] =?utf-8?q?Intel_Management_Engine_=E2=80=93_Tak?=
  28. 2018-01-28 ruben <ruben-at-mrbrklyn.com> Subject: [Hangout - NYLXS] must see digital map
  29. 2018-01-28 mrbrklyn <mrbrklyn-at-panix.com> Re: [Hangout - NYLXS] must see digital map
  30. 2018-01-28 ISOC-NY announcements <announce-at-lists.isoc-ny.org> Subject: [Hangout - NYLXS] [isoc-ny] MEETUP/WEBCAST FEB 5: Digital
  31. 2018-01-25 From: "APhA - American Pharmacists Association" <infocenter-at-aphanet.org> Subject: [Hangout - NYLXS] Immunizing Pharmacists News - January 25, 2018
  32. 2018-01-29 From: "IEEE ComSoc Meetings" <noreply-at-comsoc.org> Subject: [Hangout - NYLXS] OFC Announces 2018 Technical Program
  33. 2018-01-29 Gabor Szabo <gabor-at-szabgab.com> Subject: [Hangout - NYLXS] [Perlweekly] #340 - Back to the Future with Perl
  34. 2018-01-30 Rabbi Shaul Leiter <director-at-ascentofsafed.com> Subject: [Hangout - NYLXS] February Newsletter & IMPORTANT PURIM CAMPAIGN
  35. 2018-01-30 From: "APhA - American Pharmacists Association" <infocenter-at-aphanet.org> Subject: [Hangout - NYLXS] pharmacist.com FOCUS: FDA proposes risk-based
  36. 2018-01-30 From: "John Sullivan, FSF" <campaigns-at-fsf.org> Subject: [Hangout - NYLXS] Free Software Foundation receives $1 million
  37. 2018-01-31 eBay <eBay-at-reply1.ebay.com> Subject: [Hangout - NYLXS] eBay will begin intermediating payments on its

NYLXS are Do'ers and the first step of Doing is Joining! Join NYLXS and make a difference in your community today!